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ABSTRACT – Background: The criterion of Milan (CM) has been used as standard for indication of 
liver transplantation (LTx) for hepatocellular carcinoma (HCC) worldwide for nearly 20 years. Several 
centers have adopted criteria expanded in order to increase the number of patients eligible to liver 
transplantation, while maintaining good survival rates. In Brazil, since 2006, the criterion of Milan/Brazil 
(CMB), which disregards nodules <2 cm, is adopted, including patients with a higher number of small 
nodules. Aim: To evaluate the outcome of liver transplantation within the CMB. Methods: The medical 
records of patients with HCC undergoing liver transplantation in relation to recurrence and survival by 
comparing CM and CMB, were analyzed. Results: 414 LTx for HCC, the survival at 1 and 5 years was 84.1 
and 72.7%. Of these, 7% reached the CMB through downstaging, with survival at 1 and 5 years of 93.1 
and 71.9%. The CMB patient group that exceeded the CM (8.6%) had a survival rate of 58.1% at five years. 
There was no statistical difference in survival between the groups CM, CMB and downstaging. Vascular 
invasion (p<0.001), higher nodule size (p=0.001) and number of nodules >2 cm (p=0.028) were associated 
with relapse. The age (p=0.001), female (p<0.001), real MELD (p<0.001), vascular invasion (p=0.045) and 
number of nodes >2 cm (p<0.014) were associated with worse survival. Conclusions: CMB increased by 
8.6% indications of liver transplantation, and showed survival rates similar to CM.
RESUMO - Racional: O critério de Milão (CM) vem sendo utilizado como padrão para indicação 
do transplante hepático (TxH) por hepatocarcinoma (HCC) em todo mundo há quase 20 anos. 
Diversos centros têm adotado critérios expandidos com intuito de aumentar o número de 
pacientes candidatos ao transplante, mantendo bons índices de sobrevida. No Brasil, desde 2006, 
o critério de Milão/Brasil (CMB), que desconsidera nódulos <2 cm, é adotado, incluindo pacientes 
com maior número de nódulos pequenos. Objetivo: Avaliar o resultado do transplante hepático 
dentro do CMB. Métodos: Foram analisados os prontuários dos pacientes com HCC submetidos 
ao TxH em relação à recidiva e sobrevida através da comparação entre CM e CMB. Resultados: 
Em 414 TxH por HCC, a sobrevida em 1 e 5 anos foi de 84,1 e 72,7%. Destes, 7% atingiram 
o CMB através de downstaging, com sobrevida em 1 e 5 anos de 93,1 e 71,9%. O grupo de 
pacientes do CMB que excederam o CM (8,6%) teve sobrevida de 58,1% em cinco anos. Não 
houve diferença estatística na sobrevida entre os grupos CM, CMB e downstaging. A invasão 
vascular (p<0,001), tamanho do maior nódulo (p=0,001) e número de nódulos >2 cm (p=0,028) 
associaram-se com recidiva. A idade (p=0,001), sexo feminino (p<0,001), MELD real (p<0,001), 
invasão vascular (p=0,045) e o número de nódulos >2 cm (p<0,014) estiveram associados com a 
piora na sobrevida. Conclusões: O CMB aumentou em 8,6% as indicações de TxH e apresentou 
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The hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the sixth leading cause of cancer mortality worldwide, with an incidence of 750,000 new cases per year. Liver transplantation 
(LTx) is currently considered the best treatment for the patient with liver cirrhosis 
and HCC2,11,16.  
The MELD criteria for liver transplant waiting list, adopted in Brazil since 
2006, does not cover some serious liver diseases that lead to loss of liver function, 
such as hepatocellular carcinoma. These cases were classified as special situation 
and have received extra points, reaching the top of the waiting list for liver 
transplantation5,12,15,23.
With the special situation, patients with HCC began to take the place of 
patients with the most deteriorated and worse overall condition liver function. The 
challenge in adopting an extra score is seeking criteria that reduce the chance of 
being prioritizing patients with advanced HCC, with high risk of recurrence, instead 
of patients with higher MELD score 6,22,24,29.
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In 1996, Mazzaferro et al. introduced the Milan criteria 
(MC). Cirrhotic patients with single nodule up to 5 cm or 
up to three nodules being the largest up to 3 cm, with no 
macrovascular invasion or detectable metastasis had a survival 
rate of 75% in four years21. The concepts identified in this 
study have been widely adopted and reproduced in transplant 
centers in the world, including Brazil, where the good results 
of survival in this population was reproduced6,9,14,20,21,24. 
However, only a small portion of patients with HCC fit into 
the MC, stimulating the development of expanded criteria, 
with satisfactory results28.
Thus, other broader criteria began to emerge (Table 1) 
in order to offer more patients with hepatocellular carcinoma 
the possibility of liver transplantation, expanding the limits 
determined by the MC14,20,21,24.
TABLE 1 - Expanded criteria for liver transplantation for HCC
 
n Nodule Size (cm) Exams
Milan (16) 48 1 or 2 - 3 ≤ 5 or ≤ 3 (each) -
UCSF (19) 70 1 or 2 - 3 ≤ 6,5 ou ≤ 4,5 (sum ≤ 8) -
Navarro (20) 47 1 or 2 - 3 ≤ 6 ou ≤ 5 -
Kyoto (21) 125 ≤ 10 ≤ 5 (each) PIVKA-II< 400 (mU/mL)
Asan (22) 221 ≤ 6 ≤ 5 (each) -
Edmonton (23) 52 - Total volume ≤ 115 cm3 -
Valencia (24) 257 ≤ 3 ≤ 5 (sum ≤ 10) -
Hangzhou (25) 195 -
Total ≤ 8 cm -
Total > 8cm AFP ≤ 400, degree I/II (BX)
Up – to – seven 
(26) 1556 ≤ 7 ≤ 7 (soma) -
Toronto (27) 294
Milan Milan -
- - pathological criteria
Milan/Brazil 414
1 or 2 - 3 ≤ 5 or ≤ 3 (each)
-
(excluding nodules < 2cm)
Some comparative studies have demonstrated the 
safety of expanded the Milan criteria, to include more 
patients without increasing the HCC recurrence rate4,22. 
The implantation of MC in Brazil was followed by minor 
modifications. Nodules < 2 cm are not considered, making 
this a modified MC adopted exclusively in Brazil, called 
Milan/Brazil Criteria (MBC).
The objective of this study was to evaluate the results 
of liver transplantation with special situation for HCC using 
the MBC, after the implementation of MELD criteria.
METHOD
This study is registered in Brazil Platform and approved 
as the CEP 81706 of 21/08/2013.
Data were analyzed retrospectively by reviewing the 
medical records stored in the São Paulo State Transplantation 
Center of 414 patients undergoing LTx for HCC, conducted 
between January 2007 and December 2011 in the city of 
São Paulo.
The groups determined by preoperative imaging 
(downstaging, MBC and MC) were compared with each other 
and with respect to the results of survival and recurrence 
rates. The groups determined by pathology of explanted 
liver (MBC, CM and Out of Criteria) were compared with 
each other in relation to survival and recurrence rates.
Statistical analysis
Data were analyzed descriptively. For categorical 
variables, absolute and relative frequencies were presented. 
The numerical variables were presented in summary measures 
(mean, quartiles, minimum, maximum and standard deviation). 
The tests included the Chi-Square, Student’s t test, Mann-
Whitney, Kruskal-Wallis, the Kappa coefficient and Kaplan-
Meier survival curve. A p value <0.05 was considered 
statistically significant in all cases. Statistical analysis was 
carried out with SPSS 20.0 and STATA 12.
RESULTS
There was a predominance of Caucasian patients (80%), 
males (79.5%) with mean age of 56 years. In January 2015, 
three hundred patients were alive (72.5%). If extra points 
were not used for HCC, the MELD would be 12.6 on average 
at the time of transplant. In this study, the patients were 
on the waiting list for LTx for a year on average.
Patients were submitted to different imaging in the 
preoperative period. Was selected for the analysis the last 
imaging test performed before transplantation. Computed 
tomography (58.7%) was the test of choice in most cases, 
followed by magnetic resonance imaging (31.9%) and 
ultrasonography (9.4%). These tests were, on average, made 
four months before the LTx.
All 414 study patients met the BMC based on preoperative 
imaging. Of these, 54 (7%) passed before by downstaging 
(Table 2). Of these, 33 patients (8.6%) would be out of the 
MC; however, there is a high correlation between the two 
criteria according to the Kappa coefficient (k=0.6 – p<0.001). 






n % n % n %
Total 62 15,0% 352 85,0% 414 100,0%
No 29 100,0% 0 0,0% 29 100,0%
Yes 33 8,6% 352 91,4% 385 100,0%
Kappa 0,6 - p<0,00
The explant were sent to examination and analyzed 
the size and real number of nodes present in the explanted 
livers. Regarding pathology of explanted livers, 11.3% of 
patients were out of both criteria and 10.4% were within 
the MBC but exceeded the MC (Table 3). There was no 
statistically significant difference regarding the variables 
mortality and vascular invasion in patients included in the 
CMB, Milan criteria, or those submitted to downstaging.
In Table 4, patients groups downstaging, Milan/Brazil 
Criteria  and Milan Criteria, so classified by preoperative 
tests, were compared with the results of the pathology 
of explanted livers. Patients undergoing downstaging 
showed nodules larger than those previously classified 
by the Milan criteria. Patients classified as Criteria Milan/
Brazil had higher total number of nodes compared to the 
other two groups.
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FIGURE 1 - Results of the Kaplan-Meier survival analysis by patient characteristics, imaging and pathology
TABLE 4 - Comparison between the groups formed by preoperative imaging 
Criteria (imaging) Mean SD n p 1° Quartil Mediana n p
Size of the larger nodule* (pathology)    0,004    
0,004
 
    Downstaging 36,28A 18,82 29  23,00 35,00 29
    MC 27,77B 13,34 352  20,00 25,00 352
    MBC 24,72B 9,36 33  20,00 22,00 33
Nodules >2 cm (pathology)    0,118    
0,118     Downstaging 1,21 0,68 29  1,00 1,00 29    MC 0,97 0,72 352  1,00 1,00 352
    MBC 1,21 1,17 33  0,50 1,00 33
Nodule total number (pathology)    <0,001    
<0,001    Downstaging 2,38 1,52 29  1,00 2,00 29    MC 2,03B 1,52 352  1,00 1,00 352
    MBC 3,48A 2,50 33  2,00 3,00 33
p=descriptive level of the Kruskal-Wallis test; (A) and (B) show separate averages from Bonferroni-Dunn multiple comparisons; SD=standard deviation; *milimeters
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During the study period, were observed (7.2%) thirty 
recurrence of HCC and there was an association only between 
recurrence and vascular invasion (p<0.001). Thus, it was noted 
a higher rate of recurrence in patients with vascular invasion 
(16.5%) compared to those without this condition (4.0%). For 
the other variables, there were no associations (Table 7).
TABLE 7 - Distribution of patients for recurrence and Odds Ratio
Recurrence Total p Odds RatioNo YesN % N % N %
Gender 384 92,8% 30 7,2% 414 100,0% 0,071
   Female 75 88,2% 10 11,8% 85 100,0% 2,06
   Male 309 93,9% 20 6,1% 329 100,0% 1,00
Vascular Invasion 381 92,7% 30 7,3% 411 100,0% <0,001
   No 290 96,0% 12 4,0% 302 100,0% 1,00
   Yes 91 83,5% 18 16,5% 109 100,0% 4,78
Criteria (imaging) 384 92,8% 30 7,2% 414 100,0% 0,107a
   Downstaging 24 82,8% 5 17,2% 29 100,0% 2,98
   MC 329 93,5% 23 6,5% 352 100,0% 1,00
   MBC 31 93,9% 2 6,1% 33 100,0% 0,92
Criteria (pathology) 384 92,8% 30 7,2% 414 100,0% 0,139a
   Out of criteria 40 85,1% 7 14,9% 47 100,0% 2,53
   MC 303 93,5% 21 6,5% 324 100,0% 1,00
   MBC 41 95,3% 2 4,7% 43 100,0% 0,70
p=descriptive level of chi-square test or Fisher’s exact test(a)
There were significant differences in the variables: larger 
nodule size (p=0.005), number of nodules <2 cm (p=0.026), 
number of nodes >2 cm (p=0.028) and size of the largest nodule 
(p=0.001) in relation to recurrence rate. Thus, on average, 
patients with recurrences had higher values in these variables 
than those without recurrence. Moreover, the average number 
of lower nodes 2 cm was lower than in-group of patients with 
recurrence in the patients without recurrence (Table 8).
TABLE 8 - Summary of variable by recurrence occurrence
HCC Recurrence Mean SD n p
Age (years) 56,39 8,72 414 0,052
    No 56,16 8,84 384
    Yes 59,37 6,40 30
Real MELD 12,64 5,75 414 0,448
    No 12,56 5,60 384
    Yes 13,63 7,47 30
Number of nodule >2 cm (imaging) 1,13 0,40 332 0,487a
    No 1,12 0,39 306
    Yes 1,19 0,49 26
Size of larger nodule* (imaging) 27,91 9,39 379 0,005a
    No 27,60 9,47 353
    Yes 32,04 7,19 26
Number of nodule <2 cm (imaging) 0,63 0,97 413 0,026
    No 0,65 0,99 383
    Yes 0,37 0,61 30
Nodule, total number (imaging) 1,69 1,03 331 0,784a
    No 1,69 1,05 305
    Yes 1,62 0,75 26
Number of nodule >2 cm (pathology) 1,00 0,77 414 0,028
    No 0,98 0,77 384
    Yes 1,30 0,70 30
Size of larger nodule* (pathology) 28,13 13,71 413 0,001
    No 27,53 13,22 383
    Yes 35,83 17,29 30
Number of nodule <2 cm (pathology) 1,17 1,53 413 0,324
    No 1,19 1,55 384
    Yes 0,90 1,32 29
Nodule, total number (pathology) 2,17 1,66 413 0,992
    No 2,17 1,69 384
    Yes 2,17 1,34 29
*=measured in millimeters; p=descriptive level of the Student t test or Mann-Whitney 
TABLE 3 - Distribution of patients by Milan criteria and Milan/
Brazil criteria
Criteria n %
Criteria (imaging) 414 100,0
   MBC 33 8,0
   Downstaging 29 7,0
   MC 352 85,0
MBC – (pathology) 414 100,0
   No 47 11,3
   Yes 367 88,7
MC – (pathology) 414 100,0
   No 103 24,9
   Yes 311 75,1
MBC=Milan/Brazil criteria; MC=Milan criteria
To evaluate the effect of each of the numerical data 
variables, patient survival were adjusted to a simple Cox regression 
model (Table 5). There was a correlation between patient age 
(p=0.001), real MELD (p<0.001), number of nodules >2 cm in 
pathology (p=0.014) and survival time. Thus, every increase 
of one year in the age of the patient there is an increase of 
4.4% in the risk of death and every 1-point increase in the real 
MELD, there is a 5% increase in the risk of death. Since every 
increase of 1 nodule >2 cm in pathology, there is an increase 
of 29.2% in the risk of death.
TABLE 5 - Model results of simple Cox regression with patient 
data, imaging and pathology in relation to survival
Risk ratio (IC95%) p n
Age 1,044 (1,019 - 1,069) 0,001 414
Real MELD 1,050 (1,023 - 1,078) <0,001 414
Size of larger nodule (imaging) 1,003 (0,983 - 1,024) 0,744 379
Number of nodule >2 cm (imaging) 1,052 (0,657 - 1,687) 0,832 332
Number of nodule <2 cm (imaging) 0,944 (0,775 - 1,150) 0,567 413
Nodule total number (imaging) 1,019 (0,841 - 1,235) 0,848 331
Size of larger nodule (pathology) 1,006 (0,994 - 1,018) 0,326 413
Number of nodule >2 cm (pathology) 1,292 (1,052 - 1,586) 0,014 414
Number of nodule <2 cm (pathology) 1,035 (0,922 - 1,161) 0,562 413
Nodule total number (pathology) 1,086 (0,981 - 1,203) 0,113 413
The survival analysis Kaplan-Meier showed significance 
in relation to gender. Male patients had higher survival than 
female (p<0.001). The association of increased survival in 
patients without vascular invasion identified by histopathologic 
study was demonstrated as well (p=0.045). The other analyzed 
factors have shown no difference in survival at 1, 3 and 5 years 
(Figure 1, Table 6).
TABLE 6 - Kaplan-Meier survival analysis for patient data, 
imaging and pathology
% Survival (years) p1 3 5 
Gender <0,001
   Female 70,6 ± 4,9 60,0 ± 5,3 54,4 ± 5,7
   Male 87,2 ± 1,8 79,8 ± 2,2 75,9 ± 2,5
Vascular Invasion 0,045
   No 85,1 ± 2,0 78,0 ± 2,4 74,3 ± 2,7
   Yes 80,7 ± 3,8 69,7 ± 4,4 64,1 ± 4,7
Downstaging 0,961
   No 83,1 ± 1,9 76,1 ± 2,2 71,5 ± 2,4
   Yes 93,1 ± 4,7 71,9 ± 8,5 71,9 ± 8,5
Criteria  (imaging) 0,381
   MBC 72,7 ± 7,8 69,6 ± 8,0 58,1 ± 10,1
   Downstaging 93,1 ± 4,7 71,9 ± 8,5 71,9 ± 8,5
   MC 84,1 ± 1,9 76,7 ± 2,3 72,7 ± 2,5
Criteria (pathology) 0,279
   Out of Criteria 80,9 ± 5,7 66,0 ± 6,9 63,3 ± 7,1
   MBC 83,7 ± 5,6 74,4 ± 6,7 67,9 ± 7,5
   MC 84,3 ± 2,0 77,4 ± 2,3 73,2 ± 2,6
Estimate the probability of survival±SE; p=descriptive level of Log Rank test 
(Mantel-Cox)
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DISCUSSION
Most patients were men (79.5%), white (80%), middle-
aged (mean age 56 years), mildly overweight (BMI=26.5) 
and low value of MELD (average 12.7). Females in the 
sample showed a lower survival in Kaplan-Meier curve for 
1, 3 and 5 years (p<0.001) when compared to males (Table 
6). This result contradicts what is reported in the medical 
literature. Duffy et al. demonstrated relative risk of mortality 
of 2.43 for men (p<0.023); however, this variable was not 
significant in the multivariate analysis24. There is little data 
available in the literature relating gender as a prognostic 
factor, but few studies have reported female gender as a 
protective factor for recurrence and mortality, determining 
improved survival rate8,18,19.
The patient’s age is presented as a factor associated 
with survival (p=0.001). For each increase of one year of 
age, there is an increase of 4.4% in the risk of death (Table 
5). Other studies have identified age as a prognostic factor 
of mortality. Adler et al. in the European study for liver 
transplantation survival, in 226 patients, identified the age 
of 50 years as a risk factor for increased mortality1. 
A few studies have linked real MELD with survival of 
the transplanted patient, since this value has no influence 
on the waiting list due to the extra marks for HCC12,26. Todo 
et al. in Japan, presented a study in patients with HCC 
underwent living donor liver transplantation demonstrating 
that the real MELD influenced survival26. The results of this 
study validate the association of real MELD with survival time 
with p<0.001. For each 1-point increase in the real MELD, 
there is an increase of 5% in the risk of death (Table 5).
The waiting time for LTx for HCC patients is crucial for 
a better prognosis since the progression of the disease can 
exclude it from the queue for transplantation if nodules size 
or number exceed the MC. This rate ranges from 7-11% in 
6 months and approaches 40% at one year30. 
Some authors, however, suggest that the delay in the 
waiting list can provide a better selection of candidates 
for LTx. Patients with aggressive tumor behavior, and 
increased risk of recurrence present a greater risk of drop 
out due to faster progression of neoplasia and would not 
be transplanted25. Recent studies have shown increased 
survival after liver transplantation for HCC in patients who 
waited longer in the awaiting list14,25. 
Apparently, patients with HCC have an advantage in 
the current organ allocation system, when compared with 
patients without tumor, raising the question of including 
biological factors of poor prognosis, such as alpha-fetoprotein, 
and tumor growth rate4. Currently, the proportion of 
transplantation for HCC in São Paulo is around 33% of 
total LTx. This scenario is worrying because it coincides with 
increased mortality in the awaiting list 6,12,22,29. 
This analysis shows no association of time on the waiting 
list and survival. The mean time for the liver transplantation 
was 11.5 months in patients alive and 13 months in patients 
who died (p>0.1).
Comparing the CM, CMB and downstaging groups, 
no difference was detected regarding the occurrence of 
vascular invasion (p= 0.501). In accordance with what is 
widely reported in the literature, vascular invasion showed 
association with decreased survival. There was a significant 
difference (p 0.045), with 5-year survival of 74.3% for the 
group without vascular invasion and 64.1% for the group 
with vascular invasion. Similarly, the HCC recurrence rate 
is significantly associated with the presence of vascular 
invasion detected on pathology (p<0.001).
Following the release of the MC by Mazzaferro et 
al. in 1996, transplantation in HCC began to show better 
results, since patients with HCC to respect the limits of one 
nodule ≤5 cm or even 3 cm nodules ≤321. Most expanded 
criteria shows increasing the size and number of nodules 
in a controlled manner would result a recurrence risk and 
survival rate comparable to the MC7,9,14,20,21,24,27.
MBC disregards the counting of nodules smaller than 
2 cm and thus offers the possibility of liver transplantation 
to patients with higher number of small nodules, which 
would exceed most of the criteria cited above. Table 3 
shows the distribution of patients according to MBC, MC 
and downstaging.
Note that only a small proportion of patients selected 
for liver transplantation, the CMB has exceeded CM (8.6%), 
there is a strong correlation between the two criteria.
Analyzing the groups, the hypothesis that the MBC 
group has a higher number of nodules on biopsy compared 
to the MC is confirmed. This significant difference can be 
explained by the presence of nodules smaller than 2 cm, 
which are not accounted for at the time of indication for 
liver transplantation, but are identified on pathology of 
the explanted liver.
Applying the MBC and MB to results from the pathology 
of explanted livers, the formation of other three groups 
can be observed, adding to the first two groups the Out of 
Criteria group (OC, Table 3). This group corresponds to 47 
patients (11.3% of the sample) who did not fulfill neither 
of the two allocation criteria and therefore configure the 
failure rate in the Brazilian allocation system. Other studies 
showed a failure rate that ranged from 18-40%1,4,10. 
There was no difference in patient survival between 
the MBC and MC groups. Patients transplanted in the MBC 
had a survival rate of 72.6% at five years, comparable to the 
most important services in the world14. Considering only 
those patients who exceeded the MC, the survival rate drops 
to 58.1%, but without statistical significance. The decrease 
in survival is probably associated with higher number of 
identified nodules in the MBC group. Several studies of risk 
factors for post-LTx mortality from HCC indicate to multiple 
nodules as a criterion of poor prognosis2,16,10. 
There was no statistical difference in vascular invasion 
and survival when compared both groups, submitted or not 
to downstaging, respectively, 71.9% and 71.5% survival at 
five years (Figure 1). This result confirms the data widely 
available in the literature3,7,13,17.
The recurrence was associated with the size of the 
largest nodule, both measured by imaging preoperative 
(p=0.005) as the pathology of the explanted liver (p<0.001). 
Patients with larger nodules showed a higher recurrence 
rate. The number of nodules larger than 2 cm identified 
in pathology also been associated with the recurrence of 
HCC after liver transplantation (p<0.028).
CONCLUSION
The CMB increased by 8.6% indications of liver 
transplantation, and showed survival rates similar to CM.
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